USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Roche Glycart Ag

USPTO PatentsView assignee record — 55 granted patents across 11 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).

55
Total patents granted
11
CPC technology areas
19.6
Avg claims per patent
-66%
5-year filing velocity

The verdict

Roche holds 55 US patents across 11 technology areas — rank #6,183 of 50,000 tracked assignees.

#6,183
of 50,000 US assignees by volume
Top 38%
by Innovation Score (39.6/100)
19.6
avg claims per patent
-66%
filing velocity, last 5 yrs

Portfolio overview

Roche Glycart AG has been granted 55 US utility patents between 2015 and 2025, placing Roche Glycart AG at rank #6,183 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.6 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Roche Glycart AG is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 39.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 14 grants, compared with 41 in the 2015–2019 window — a -66% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Roche Glycart AG's 19.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Roche Glycart AG against peers pursuing similar technology classes.

How does Roche compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Roche holds 55 patents — placing it at rank #6,183 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

40 Top 38% higher than 62% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

051015 2015201620172018201920202021202220232025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Roche Glycart AG patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 8 14.5%
2016 12 21.8%
2017 6 10.9%
2018 8 14.5%
2019 7 12.7%
2020 5 9.1%
2021 3 5.5%
2022 4 7.3%
2023 1 1.8%
2025 1 1.8%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#6,183

Across all tracked assignees

Innovation Score

39.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Roche Glycart AG hold?
Roche Glycart AG holds 55 US granted patents filed between 2015 and 2025, spanning 11 technology areas.
What is Roche Glycart AG's Innovation Score?
Roche Glycart AG has an Innovation Score of 39.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Roche Glycart AG focus on?
Roche Glycart AG's top technology area is C07K (PEPTIDES) with 55 patents. The company has filed patents in 11 CPC subclasses total.
Is Roche Glycart AG's patent filing rate increasing or decreasing?
Roche Glycart AG's recent filing velocity is -66% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Roche Glycart AG's patents?
Roche Glycart AG's patents average 19.6 claims each. This falls within the standard range, providing solid legal coverage.
How is the Roche Glycart AG patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Roche's 55 grants land it in the top 38% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Roche ranks #6,183 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C07K — see who else leads that technology area. C07K leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov